120 RBp135 MANAGEMENT OF AN ECTOPIC SELLAR TRILATERAL RETINOBLASTOMA Rana’a Al-Jamal, Sanna Seitsonen, Ulla Pihkala, Matti Tenhunen, Päivi Lindahl, Leena Koskinen, Tero Kivelä 350 RBp136 MOLECULAR PATHWAYS OF RETINOBLASTOMA RE- VEALED THROUGH GLOBAL PROTEOMICS ANALYSES OF Y79 AND CHLA215 CELL LINES: A DRUG RESIS- TANCE CASE STUDY Susan Lee, Robert Fanter, Narine Harutyunyan, Joanne Lee, A Linn Murphree 1950 RBp137 EVALUATING THE GLYCOLYTIC PATHWAY IN RETINO- BLASTOMA: A MECHANISTIC APPROACH USING THE GLYCOLYTIC INHIBITOR 2-DEOXY-D-GLUCOSE IN VIT- RO AND IN VIVO Christina L. Decatur, Yolanda Piña, Samuel Houston, Elizabeth Sullivan, RETINOBLASTOMA <strong>Program</strong> 34 Huaping Liu, Theodore Lampidis, Timothy G. Murray 101 RBp138 REGIONAL AND TEMPORAL VARIATIONS IN GENE EXPRESSION AND VASCULATURE DURING RETINO- BLASTOMA TUMORIGENESIS AND ITS IMPACT ON OCULAR TREATMENT Yolanda Piña, Timothy G. Murray, Christina L. Decatur, Nikesh Shah, Ludimila Cavalcante, and Samuel Houston
152 RB1 GUIDELINES FOR IMAGING OF RETINOBLASTOMA: DIAGNOSTIC IMAGING STRATEGY AND STANDARDIZED MR IMAGING PROTOCOL P. de Graaf1 , S. Göricke2 , F. Rodjan1, P. Galluzzi3, P. Maeder4 , J.A. Castelijns1, H.J. Brisse5 on behalf of the European Retinoblastoma Imaging Collaboration (ERIC) (p.degraaf@vumc.nl) 1. Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands 2. Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital, Essen, Germany 3. Unit of Diagnostic and Therapeutic Neuroradiology, Azienda Ospedaliera e Universitaria Senese, Policlinico “Le Scotte”, Siena, Italy 4. Service de Radiodiagnostic et Radiologie Interventionelle, CHUV, Lausanne, Switzerland 5. Département d’Imagerie, Institut Curie, Paris, France Purpose. Diagnosis of retinoblastoma is usually established by the ophthalmologist on the basis of fundoscopy and ultrasound (US). Together with US, high-resolution MR imaging has emerged as an important imaging modality for the pretreatment assessment of retinoblastoma, i.e., for diagnostic confirmation, detection of local tumor extent and depiction of associated brain abnormalities (developmental malformation, or trilateral retinoblastoma, i.e., intracranial primitive neuroectodermal tumor). MR imaging is currently performed in the work-up for retinoblastoma in many institutions around the world. However, diagnostic accuracy for detection of high-risk features, especially optic nerve infiltration, is highly dependend on technical quality of MR images. Thus, there is the need for a standardized protocol with minimal requirements for imaging retinoblastoma. Methods. In this imaging guideline, the minimum requirements for pretreatment diagnostic evaluation of retinoblastoma or mimicking lesions are presented, according to the consensus reached between members of the European Retinoblastoma Imaging Collaboration (ERIC). Results. The most appropriate techniques for state-of -the-art diagnostic imaging of a child with leukocoria are reviewed. CT is no longer recommended. A standardized MR imaging protocol was developed, including detailed technical requirements and specific imaging stategies for unilateral and bilateral disease. Conclusions. Implementation of a standardized MR imaging protocol for retinoblastoma in clinical practice will allow a state-of-the-art radiologic evaluation for the detection of tumor extent. Financial disclosure. None 1831 RB2 CHEMOTHERAPY FOCAL THERAPY AND BEYOND: THE IMPORTANCE OF CLINICAL TRIALS & THE ROLE OF A RETINOBLASTOMA CLINICAL STUDIES CONGLOMERATE Helen Dimaras1, Ashwin C. Mallipatna2, Brenda L. Gallie1, Helen S.L. Chan1.(helen.dimaras@utoronto.ca) 1. The Hospital for Sick Children and The University of Toronto 2. Narayana Nethralaya Hospital RETINOBLASTOMA Abstracts 35 Purpose The National Retinoblastoma Strategy Canadian Guidelines for Care point out the absence of Class A evidence (randomized clinical trials) to guide therapy. Consequently, consensus recommendations and current practice at Retinoblastoma Centres underpin the Guidelines. Because retinoblastoma is rare, few clinical trials have been completed. Methods. We undertook search of the NIH Clinical Trials Database using the search term ‘retinoblastoma’ (http://clinicaltrials.gov/ ct2/results?term=retinoblastoma). The results of this search were categorized purpose, country, and number of centres involved, and publications that ensued. Results were used to inform suggested directives for retinoblastoma clinical research. Results. Our search yielded 54 hits, in which 19 trials studied the efficacy of a treatment specifically targeting retinoblastoma patients. Only 6 were multicentre trials, with most participating centres in highincome countries. There was little representation of middle-income countries (3/19 studies), and none of low-income countries (0/19 studies), where most children with retinoblastoma reside. Most results were unpublished; those published were limited in scope and study numbers. Conclusions. Clinical trials are the gold standard for evidence-based care, as they ascertain utility, efficacy and safety of new methods. Despite this, the few retinoblastoma clinical trials target only a small proportion of affected children in rich countries, resulting in small and often homogenous study populations, with results that may not be applicable to children around the world. As shown in other pediatric cancers, conducting rigorous, significant, multicentre trials led by multidisciplinary teams will most effectively improve care for all retinoblastoma children. We propose a retinoblastoma clinical studies conglomerate to develop, conduct and evaluate novel clinical studies that contribute to evidence based care. Since only 9000 children each year are newly diagnosed, clinical trials could involve all eligible children. Financial disclosure. None 1846 RB3 RETINOBLASTOMA: ANALYSIS OF MORTALITY IN UZBEKISTAN Z. Islamov, F. Islom (dr_islamov@yahoo.com) National Center of Oncology, Uzbekistan Mercer University, United States Purpose. We sought to analyze mortality from retinoblastoma and identify factors that predispose to these deaths. Methods. From 2001 to 2010, 314 patients age
- Page 1 and 2: XV th NH City Hotel and Tower Boliv
- Page 3 and 4: List of Congress Meetings of the In
- Page 5: Table of Contents Welcome address K
- Page 8 and 9: Keynote Lectures Lymphoma of the oc
- Page 10 and 11: The venue for the Biannual Meeting
- Page 12 and 13: Buenos Aires Downtown MAP 12 Venue
- Page 15 and 16: MORNING 8.30-10.10 Papers (Moderato
- Page 17 and 18: 50 RES 26 USING THE GLYCOLYTIC INHI
- Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
- Page 21 and 22: a reduction in the number of living
- Page 23 and 24: array further detected copy number
- Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
- Page 27: following treatment with 2-fluorode
- Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
- Page 32 and 33: Posters Retinoblastoma 2006 RBp100
- Page 36 and 37: After treatment, 10 patients lived
- Page 38 and 39: Methods. Six cycles of carboplatin
- Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
- Page 42 and 43: 4. Fluoroscopy for cannula placemen
- Page 44 and 45: Methods. A retrospective chart revi
- Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
- Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
- Page 50 and 51: months. Mean delay between beginnin
- Page 52 and 53: not associated with severity of RB.
- Page 54 and 55: Conclusions. During a ten-year peri
- Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
- Page 58 and 59: (follow-up 5 years). Two years afte
- Page 61 and 62: 8.30-9.00 Poster presentations ECOp
- Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
- Page 65 and 66: Morning 8.30-9.00 Poster presentati
- Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
- Page 69 and 70: Purpose. Ocular surface squamous ne
- Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
- Page 73 and 74: of the tissues most commonly affect
- Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
- Page 77 and 78: Ocular Oncology Service, St Barthol
- Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
- Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
- Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
- Page 85 and 86:
patients. The isolated involvement
- Page 87 and 88:
exudative fluid from the hemangioma
- Page 89:
maximum of 7 rituximab injections.
- Page 92 and 93:
153 UM14 PHENO-GENOTYPIC IDENTIFICA
- Page 94 and 95:
8.30-9.00 Poster presentations UMp1
- Page 96 and 97:
2253 UM1 PRELIMINARY STUDY OF VASCU
- Page 98 and 99:
Purpose. To determine the presence
- Page 100 and 101:
gene expression profile of melanocy
- Page 102 and 103:
the rarity of UM, timely completion
- Page 104 and 105:
C. Metz, T. Gkika, W. Sauerwein, N.
- Page 106 and 107:
Patients in the triamcinolone group
- Page 108 and 109:
1350 Ump101 INDUCED EXPRESSION OF P
- Page 110 and 111:
Purpose. To report the Results of R
- Page 112 and 113:
1547 Ump113 LONG-TERM OBSERVATIONS
- Page 114 and 115:
2038 Ump119 VALUE OF DOPPLER ANALYS
- Page 116:
Methods. A total of 4070 patients w
- Page 119:
First authors Naseripour, Masood No
Change language